Articles From: ON Semiconductor Reports Second Quarter 2014 Results to OncoSec Medical Announces October Events Agenda


ON Semiconductor Corporation (Nasdaq: ONNN ) For the second quarter of 2014, highlights include: Total revenues of $757.6 million GAAP gross margin of 36.0 percent Non-GAAP gross margin of 36.2 percent GAAP net income per diluted share of $0.20 Non-GAAP net income per diluted share of $0.20 ON Semiconductor Corporation (Nasdaq: ONNN ), driving energy efficient innovation, today announced that total revenues in the second quarter of 2014 were $757.6 million, up approximately 7.2 percent compared to the first quarter of 2014.
Sign-up for ON Semiconductor Reports Second Quarter 2014 Results investment picks
2014/9/30
BETHESDA, Md.
Sign-up for On the Road: Marriott Rewards Named "Best in Business" in Travel + Leisure and Fortune Survey investment picks
As the prime contractor responsible for the Federal Aviation Administration’s (FAA) execution of the Automatic Dependent Surveillance-Broadcast (ADS-B) program, Exelis (NYSE: XLS ) is delivering surveillance coverage requirements on budget and on schedule.
Sign-up for On Track: Exelis ADS-B Program Delivering Benefits Now investment picks
2014/8/28
ADVISORY, Aug.
Sign-up for Once The Musical to Ring The NASDAQ Stock Market Closing Bell investment picks
2014/7/24
Onco360, the nation’s fastest-growing independent Oncology Pharmacy and Clinical Support Services company, today announced that it has been selected to be part of the highly limited Specialty Pharmacy network of Zydelig (idelalisib) tablets.
Sign-up for Onco360® Named to Zydelig® (Idelalisib) Limited Distribution Network; Zydelig is Available Immediately for Order Through Onco360 investment picks
OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-Resistant Prostate Cancer Canada NewsWire BOTHELL, Wash.
Sign-up for OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-Resistant Prostate Cancer investment picks
ENSPIRIT Trial to Continue as Planned Following Completion of the First of Two Interim Futility Analyses BOTHELL, Wash.
Sign-up for OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer investment picks
OncoGenex Pharmaceuticals Announces Appointment of John A.
Sign-up for OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer investment picks
2014/8/7
Conference call to be held on Thursday, August 7, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash.
Sign-up for OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2014 investment picks
2014/9/16
Oncolytics Biotech® Inc. Announces Overall and KRAS-Mutated Patient Data from U.S. Randomized Phase 2 Pancreatic Cancer Study Canada NewsWire TORONTO , Sept.
Sign-up for Oncolytics Biotech® Inc. Announces Overall and KRAS-Mutated Patient Data from U.S. Randomized Phase 2 Pancreatic Cancer Study investment picks
2014/8/7
CALGARY , Aug.
Sign-up for Oncolytics Biotech® Inc. Announces Second Quarter 2014 Results investment picks
REDWOOD CITY, Calif., Aug.
Sign-up for OncoMed Pharmaceuticals Announces Removal of Partial Clinical Hold by the FDA for Vantictumab investment picks
REDWOOD CITY, Calif., Aug.
Sign-up for OncoMed Pharmaceuticals Announces Second Quarter 2014 Financial Results investment picks
REDWOOD CITY, Calif., July 2, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED) , a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced the issuance of a broad U.S. patent relating to FZD-Fc soluble receptors, including OncoMed's clinical-stage candidate ipafricept (FZD8-Fc, OMP-54F28). The new patent, U.S. Patent No.
Sign-up for OncoMed Pharmaceuticals Granted Broad FZD-Fc Composition-of-Matter and Use Patent in U.S. investment picks
REDWOOD CITY, Calif., July 16, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED) , a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that patient dosing has begun in the randomized, placebo-controlled Phase 2 portion of the company's " ALPINE " ( A ntibody therapy in first- L ine P ancreatic cancer I nvestigating anti- N otch E fficacy and safety) clinical trial of its anti-Notch 2/3 cancer stem cell antibody, tarextumab (OMP-59R5), being studied for the treatment of pancreatic cancer.
Sign-up for OncoMed Pharmaceuticals Initiates Randomized Phase 2 "ALPINE" Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) for Pancreatic Cancer investment picks
REDWOOD CITY, Calif., Oct.
Sign-up for OncoMed Pharmaceuticals to Present at the 13th Annual BIO Investor Forum investment picks
REDWOOD CITY, Calif., Sept.
Sign-up for OncoMed Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference investment picks
MADRID and REDWOOD CITY, Calif, Sept.
Sign-up for OncoMed's Demcizumab Phase 1b Clinical Trials Show Encouraging Safety and Anti-Tumor Activity at ESMO investment picks
OncoSec Medical Inc. (OTCQB: ONCS ), a company developing DNA-based intratumoral cancer immunotherapies, will attend or present at three events in October.
Sign-up for OncoSec Medical Announces October Events Agenda investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: ON Semiconductor Reports Second Quarter 2014 Results to OncoSec Medical Announces October Events Agenda
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices